Cancer Loyalty Card Study 2 (CLOCS-2)
NCT06447064 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2900
Last updated 2026-03-25
Summary
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.
Therefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.
The major reasons for not presenting to the GP with symptoms such as these are "not wanting to waste the GP's time" and normalisation of these symptoms.
The persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.
RATIONALE FOR CURRENT STUDY
An early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.
Information about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.
Conditions
- Pancreatic Cancer
- Colon Cancer
- Oesophageal Cancer
- Stomach Cancer
- Liver Cancer
- Bladder Cancer
- Uterine Cancer
- Vulvar Cancer
- Ovarian Cancer
- Endometrial Cancer
Interventions
- OTHER
-
Cases & Controls
Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will only need to provide a photo ID and utility bill for ID verification, if the retailer cannot match participant details. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
Sponsors & Collaborators
-
University of Birmingham
collaborator OTHER -
University of Nottingham
collaborator OTHER -
University of Central Lancashire
collaborator OTHER - collaborator OTHER
-
Imperial College Healthcare NHS Trust
collaborator OTHER -
Imperial College London
lead OTHER
Principal Investigators
-
Dr James Flanagan · Imperial College London
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-02-04
- Primary Completion
- 2027-02-28
- Completion
- 2027-04-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
NCT07070713 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
NCT03414983 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
NCT06341309 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
NCT02149108 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
NCT01067053 ·Status: UNKNOWN ·Phase: PHASE2
-
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT03446157 ·Status: COMPLETED ·Phase: PHASE2
-
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
NCT00044343 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
NCT06341296 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
NCT00202774 ·Status: COMPLETED ·Phase: PHASE3
-
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
NCT00193167 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
NCT02119026 ·Status: COMPLETED ·Phase: PHASE2
-
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
NCT05412706 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
NCT02060188 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
NCT00063141 ·Status: COMPLETED ·Phase: PHASE3
-
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
NCT03009058 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
EMVI as a Determinant of Metastasis in Colorectal Cancer
NCT06646341 ·Status: RECRUITING
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
NCT04963283 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
NCT05219435 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
NCT03981146 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
NCT06540326 ·Status: RECRUITING ·Phase: PHASE2
-
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00017082 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
NCT00514761 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
NCT00022698 ·Status: COMPLETED ·Phase: PHASE2